(PEG) Pharma Equity Cl - Ratings and Ratios

Pharma Equity Group A/S, through its subsidiary Reponex Pharmaceuticals A/S, operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for high-impact diseases where existing therapies are insufficient or outdated. The companys pipeline includes multiple Phase II clinical-stage candidates: RNX-011 for bacterial peritonitis, RNX-021, RNX-022, and RNX-023 for chronic skin ulcers, RNX-041 for inflammatory bowel diseases such as Crohns and pouchitis, and RNX-051 for colorectal cancer and colon adenoma. Founded in 2002, Pharma Equity Group is headquartered in Horsholm, Denmark, and is listed under the ticker symbol PEG on the CO exchange. The company falls under the Coal & Consumable Fuels sector, though its operations are entirely within biopharmaceuticals.

From a technical standpoint, PEG has shown a bearish trend, trading below its SMA 20 and SMA 50 at 0.14, with an ATR of 0.01, indicating low volatility. The stocks average 20-day volume is 702,902, reflecting moderate liquidity. On the fundamental side, the company has a market cap of 184.74M DKK, with a price-to-book ratio of 9.68, suggesting a premium valuation relative to book value. The lack of P/E and forward P/E indicates the company is pre-profit or in a developmental stage.